Studies presented this week both claim that Pradaxa and Eliquis cause less major bleeding events than warfarin, amid continuing injury lawsuits filed by users of the new-generation anticoagulants.
A new ISMP QuarterWatch report warns that bleeding problems with Pradaxa appear to be the more dangerous than those associated with Xarleto or Eliquis.
A new study finds that Pradaxa and Xarelto are no safer than warfarin and similar drugs and warns that the lack of reversal agents and patient monitoring may increase risk…
Pradaxa and Xarelto should not be given to patients with chronic kidney disease, health experts warn.
An investigative report reveals misuse of Coumadin in nursing homes, resulting in resident injuries and deaths.
Researchers warn that they have detected that the blood thinner Xarelto rapidly crosses the placenta, which raises questions about the safety of the anticoagulant among pregnant women.
Bristol-Myers Squibb faces an Eliquis lawsuit brought by a Virginia woman, who alleges that her husband's wrongful death was caused by side effects of the anticoagulant.
A new reversal agent being tested for Pradaxa stopped the drug's blood thinning effects within minutes, according to a study sponsored by the drug's manufacturer.
Manufacturers of Xarelto, Pradaxa and other new blood thinners have not provided enough data on routine monitoring to determine whether it would help prevent bleeding incidents, Australian regulators report.
The rules for an upcoming "science day" in the Xarelto litigation have been released by the U.S. District Judge presiding over the lawsuits.